trade name fully human monoclonal antibody developed treatment solid tumors drug developed imclone systems inc isolated native phage display library dyax april us food drug administration fda approved ramucirumab singleagent treatment advanced gastric cancer gastroesophageal junction gej adenocarcinoma prior treatment fluoropyrimidine platinumcontaining chemotherapy approval based results regard trial phase iii international randomized doubleblind placebocontrolled study evaluated safety efficacy ramucirumab combinated best supportive care versus trial criticised use placebo control arm reflect standard care western ramucirumab also studied combination paclitaxel type chemotherapy received additional fda approval november treatment people advanced gastric cancer gej adenocarcinoma prior treatment fluoropyrimidine platinumbased chemotherapy approval based results rainbow trial compared ramucirumab plus paclitaxel paclitaxel december fda approved ramucirumab combination docetaxel treatment metastatic nonsmallcell lung carcinoma nsclc disease progression firstline platinumcontaining chemotherapy approval based revel april ramucirumab approved fda treatment patients metastatic colorectal cancer mcrc disease progression prior therapy bevacizumab oxaliplatin fluoropyrimidine approval based results raise trial phase iii study compared ramucirumab plus irinotecan folinic acid folfiri folfiri may ramucirumab approved fda single agent treatment hepatocellular carcinoma hcc patients alpha fetoprotein afp ngml previously treated approval based multinational randomized doubleblind placebocontrolled multicenter study patients advanced hcc afp ngml disease progression sorafenib intolerant estimated median overall survival os months months patients receiving ramucirumab months months receiving placebo european approval nsclc therapy ramucirumab contraindicated tumour cavitation major vessels common adverse effects study investigating ramucirumab monotherapy diarrhoea patients compared placebo hyponatraemia low blood sodium levels versus headache versus high blood pressure versus studies interactions observed paclitaxel docetaxel ramucirumab direct antagonist binds high affinity extracellular domain block binding natural vegfr ligands vegfa vegfc vegfd ligands secreted solid tumors promote angiogenesis formation new blood vessels preexisting ones enhance tumor blood supply binding ramucirumab leads inhibition vegfmediated tumor september manufacturer eli lilly announced phase iii study ramucirumab failed hit primary endpoint progressionfree survival among women metastatic breast june phase iii trial drug reported failed improve overall survival liver feb reported phase ii trial adding ramucirumab docetaxel improved progressionfree survival pfs compared docetaxel alone locally advanced metastatic urothelial range phase iii trial hospitals italy conducted multicentre randomised doubleblind placebocontrolled phase trial evaluate safety effectiveness antibody ramucirumab combined gemcitabine patients pretreated pleural mesothelioma combining ramucirumab standard second line gemcitabine significantly improved overall survival failure firstline chemotherapy favourable safety httpsenwikipediaorgwikiramucirumab